MedTrace Logo

A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")

NCT00839241 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2021-11-11

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to compare the immunological status after either autologous blood transfusion as administered by Bellovac® ABT or allogenic blood transfusion, with regards to change in Natural Killer (NK) cell frequency in patients undergoing total knee replacement.

Conditions

  • Arthroplasty, Replacement, Knee
  • Blood Transfusion, Autologous
  • Blood Transfusion

Interventions

DEVICE

Bellovac ABT

Bellovac ABT (autologous blood)

PROCEDURE

Allogenic Blood Transfusion

Transfusion of allogenic ("bank") blood.

Sponsors & Collaborators

  • Wellspect HealthCare

    lead INDUSTRY

Principal Investigators

  • Magnus Jacobsson, MD, PhD, Prof. · Dentsply Sirona Implants and Consumables

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839241 on ClinicalTrials.gov